PR NewswireLondon, March 15 NET ASSET VALUE BLACKROCK GREATER EUROPE INVESTMENT TRUST PLC 5493003R8FJ6I76ZUW55 The unaudited net asset values for BlackRock Greater Europe Investment Trust plc at c... Reported by FinanzNachrichten.de 2 hours ago.

Amundi-backed IM Square aims to spend $500m on deals in Europe and the US Reported by FT.com 2 hours ago.

PR NewswireLondon, March 15 NET ASSET VALUE BLACKROCK EMERGING EUROPE PLC 549300OGTQA24Y3KMI14 The unaudited net asset values for BlackRock Emerging Europe plc at close of business on 15 March 201... Reported by FinanzNachrichten.de 2 hours ago.

NEW YORK, NY, March 16, 2018 (GLOBE NEWSWIRE) -- Metrospaces, Inc. (OTC: MSPC) announces that Etelix increased February revenue by 13% over January.

Mr. Leandro Iglesias, Etelix CEO, stated: “Our business plan continues in frank execution with continued and notable revenue growth not just year-over-year but also month-over-month.  Continued reinvestment from operation has been key in growing revenue and this is a trend that must continue in order to meet our mid-year estimates or $1 million in monthly revenue.  February 2018 revenue closed at $726,365 in comparison to $644,147 in 2017.  This represents an increase of approximately 13% year-over-year and an increase of also 13% month-over-month.  Additionally, we signed Vodafone India into our carrier VoIP exchange business, setting the first step of a potentially multi-service relationship. Vodafone India has over 211 million retail subscribers interconnected to Etelix’s international VoIP exchange and value-added services.  I will congratulate the rest of our management team for a great job as the company continues to meet its short, mid and long-term revenue and profit growth.  The company foresees continue reinvestment of operating profits to continue to grow the business, as the company will continue to generate more revenue opportunities that it is able to finance with cash flow.”

*About Etelix.com USA, LLC*

*Etelix.com USA (*http://www.etelix.com/) is a Miami-based, FCC-licensed voice, SMS and data/hosting operator. The company’s main products and services are international voice wholesale, data and hosting services as well as residential and commercial triple-play provider.  The company was founded in 2007 and has been profitable since inception. 

*About Metrospaces*

Metrospaces *www.metrospaces.net*  is a publicly traded real estate investment and Development Company which invests in real estate projects and operating companies with a very strong real estate component.   It is operated by an elite group of real estate and investment professionals and entrepreneurs located in New York City, Miami and Buenos Aires. Company shareholders have extensive careers in real estate and business financing worldwide, and have funded projects both in the America’s and across Europe valued in excess of US $550Million.

Metrospaces’ majority shareholders has partnered with Investors on Elite properties including The London  BLVGARI 5 Star Hotel, Ilal del Mar (Playa del Carmen, now part of the Viceroy Chain of Hotels) and is currently involved in negotiations for the development of several Elite luxury properties in South America.

Among Metrospace partners are Architects, Real Estate Developers, Agents and Attorneys of the highest standing, with extensive experience in the global property market.

*Metrospaces *was originally founded by company President Oscar Brito.

*Relevant Links:*

http://metrospaces.net/*Safe Harbor Statement:*

Statements in this news release may be “forward-looking statements”.  Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release and Metrospaces Inc. undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release.

CONTACT: Company Contact: Tel: 305-600-0407

Investor Relations: investors@metrospaces.net Reported by GlobeNewswire 2 hours ago.

The draws for the quarter-finals for the UEFA Champions League were announced during a ceremony in Lyon on Friday.

There was bitter-sweet news for fans of English football as the last two surviving teams from the Premier League - Manchester City and Liverpool - were drawn against each other. While this will no doubt make for an exciting contest, it'll also enure just one English team's advancement to the semi-final stage of Europe's premier club competition.

 

Juventus were given a chance to avenge last year's Champions League final defeat by Real Madrid when they two sides were drawn together for the quarter-finals of this year's competition. The Serie A side, beaten 4-1 in Cardiff last season, will host the first leg in Turin following the draw at UEFA headquarters.

 

La Liga leaders Barcelona will face AS Roma, bringing back unhappy memories for the Italian side who lost 6-1 on their last visit to Camp Nou.

Sevilla, responsible for knocking out Manchester United, were pitted against German's Bayern Munich.

-*Here's the full draw*-

1. FC Barcelona v/s AS Roma

2. Sevilla FC v/s FC Bayern Munich

3. Juventus FC v/s Real Madrid CF

4. Liverpool FC v/s Manchester City FC

​*Note: The teams mentioned first will play the first leg of the tie at home.

 

Article Type: 
Report
Sections: 
Sports
Authors: 
DNA Web Team
Agencies: 
DNA webdesk
Tags: 
Football
soccer
Champions League
UEFA Champions League
Champions League draw
Lyon
KIEV
Real Madrid
Barcelona
Sevilla
Liverpool
AS Roma
Manchester City
Juventus
Bayern Munich
Web Exclusive
Turin
english
Serie A
German
Italian
UEFA
Cardiff
Camp Nou
Fri, 16 Mar 2018-04:53pm
Date updated: 
Friday, 16 March 2018 - 5:18pm
Article Images: 
AFP
Short URL: 
dnai.in/fjgR
Embargo: 
Syndicate: 
Hide lead image: 
Page views: 
2
Related Articles: 
Champions League centurion Lionel Messi still has more goals to achieve
After Sevilla defeat, Mourinho reminds fans of Man Utd's failures in CL during Ferguson era
'God save the king': Magical Messi slays Chelsea in Champions League, reaches 100 goals
From Print Edition: 
Highlights:  Reported by DNA 2 hours ago.

INDIANAPOLIS, March 16, 2018 (GLOBE NEWSWIRE) -- Hurco Companies, Inc. (Nasdaq:HURC) today announced that its Board of Directors approved the payment of a cash dividend of $0.11 per share of common stock.  The dividend will be paid on April 16, 2018, to shareholders of record as of the close of business on April 2, 2018.  Future declarations of dividends are subject to approval of the Board of Directors and may be adjusted as business needs or market conditions change.Hurco Companies, Inc. is an international, industrial technology company that sells its three brands of computer numeric control (CNC) machine tools to the worldwide metal cutting and metal forming industry. Two of the Company’s brands of machine tools, Hurco and Milltronics, are equipped with interactive controls that include software that is proprietary to each respective brand. The Company designs these controls and develops the software. The third brand of CNC machine tools, Takumi, is equipped with industrial controls that are produced by third parties, which allows the customer to decide the type of control added to the Takumi CNC machine tool. The end markets for the Company's products are independent job shops, short-run manufacturing operations within large corporations, and manufacturers with production-oriented operations. The Company’s customers manufacture precision parts, tools, dies, and/or molds for industries such as aerospace, defense, medical equipment, energy, transportation and computer equipment. The Company is based in Indianapolis, Indiana, with manufacturing operations in Taiwan, Italy, the U.S. and China, and sells its products through direct and indirect sales forces throughout North and South America, Europe, and Asia. The Company has sales, application engineering support and service subsidiaries in China, England, France, Germany, India, Italy, Poland, Singapore, South Africa, the U.S., and Taiwan. Web Site: www.hurco.com

Certain statements in this news release are forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These factors include, among others, the cyclical nature of the machine tool industry, changes in general economic and business conditions that affect demand for our products, the risks of our international operations, changes in manufacturing markets, innovations by competitors, the ability to protect our intellectual property, breaches of our network and system security measures, fluctuations in foreign currency exchange rates, increases in prices of raw materials, quality and delivery performance by our vendors, our ability to effectively integrate acquisitions, negative or unforeseen tax consequences and governmental actions and initiatives including import and export restrictions and tariffs.

Contact:
Sonja K. McClelland
Executive Vice President, Secretary, Treasurer, & Chief Financial Officer
317-293-5309 Reported by GlobeNewswire 2 hours ago.

Subject to testing and regulatory approval, Nasdaq Commodities is planning to list German Only Electricity Day and Week contracts on April 23, 2018.

The contracts will be settled against the average of the hourly prices from the day-ahead auction for the German/Austrian price zone until the split of the German/Austrian price zone and thereafter against the average of the hourly prices from the day-ahead auction for the German price zone.

*Quotation List*
As of launch date April 23, 2018, there will be four (4) weekly German Only Electricity Base and Peak Average Rate futures contracts and eight (8) daily German Only Electricity Base futures contracts listed. The nearest week and day contract available for trading and clearing will be week 18, 2018 and day April 25, 2018.

Weekly Base and Peak Load Futures Contracts

EDEFBW18-18   EDEFPW18-18      
EDEFBW19-18   EDEFPW19-18
EDEFBW20-18   EDEFPW20-18
EDEFBW21-18   EDEFPW21-18Daily Base Load Futures Contracts

EDEFBD2504-18, EDEFBD2604-18, EDEFBD2704-18, EDEFBD2804-18, EDEFBD2904-18,
EDEFBD3004-18, EDEFBD0105-18, EDEFBD0205-18

From April 30, there will be five (5) weekly German Only Base and Peak Average Rate Futures contracts listed. From April 24 there will be nine (9) daily German Only futures contracts listed. Please see the quotation list below:

 

*Electricity Contracts* *Number of Contracts listed*
*German Only Electricity Base and Peak Average Rate Week Futures* 5
*German Only Electricity Base Day Futures* 9

 

The trading and clearing rules and the product calendar of Nasdaq Commodities will be updated to reflect these changes in due course.

 

*For further information, please contact Nasdaq Commodities:*

Arman Mohii, Nasdaq Commodities Products, phone +46 73 449 7850, arman.mohii@nasdaq.com

Knut Rabbe, Head of Sales Commodities Europe, phone +47 6752 8032/+47 9322 0800, knut.rabbe@nasdaq.com   

Anja Weiss, Sales Director Central Europe, phone +44 07880386321, anja.weiss@nasdaq.com

 

*About Nasdaq *

Nasdaq (Nasdaq: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today’s global capital markets.  As the creator of the world’s first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,600 listed companies with a market value of over $8.8 trillion and more than 10,000 corporate clients. To learn more, visit www.nasdaq.com/ambition or www.nasdaqomx.com.

 

*About Nasdaq Commodities*

Nasdaq Commodities is the brand name for the worldwide suite of commodity related products and services offered by Nasdaq. The Nasdaq Commodities offerings include power, natural gas and carbon emission markets, tanker and dry cargo freight, fuel oil, seafood derivatives, iron ore, electricity certificates and clearing services.

Nasdaq Oslo ASA is the commodity derivatives exchange authorized by the Norwegian Ministry of Finance and supervised by the Norwegian Financial Supervisory Authority. All trades with Nasdaq Oslo ASA are subject to clearing with Nasdaq Clearing.

 

*About Nasdaq Clearing*

Nasdaq Clearing is the trade name of Nasdaq Clearing AB which is authorized and supervised as a multi-asset clearinghouse by the Swedish Financial Supervisory Authority in Sweden as well as authorized to conduct clearing operation in Norway by the Norwegian Ministry of Finance.For more information, visit www.nasdaqomx.com/commodities

The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Neither The Nasdaq Group, Inc. nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

  Reported by GlobeNewswire 2 hours ago.

The latest market research report by Technavio on the global heat interface units marketpredicts a CAGR of over 7% during the period 2018-2022. This press release features multimedia. View the ful... Reported by FinanzNachrichten.de 2 hours ago.

*FORM 8.3*

*PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY *
*A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE*
*Rule 8.3 of the Takeover Code (the "Code")*

*1.         KEY INFORMATION*

*(a) Full name of discloser:* OZ Management LP and
Och-Ziff Management Europe Ltd
*(b) Owner or controller of interests and short positions disclosed, if different from 1(a):*
     The naming of nominee or vehicle companies is insufficient.  For a trust, the trustee(s), settlor and beneficiaries must be named.  
*(c) Name of offeror/offeree in relation to whose relevant securities this form relates:*
     Use a separate form for each offeror/offeree GKN plc
*(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:*  
*(e) Date position held/dealing undertaken:*
     For an opening position disclosure, state the latest practicable date prior to the disclosure 15 March 2018
*(f)  In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?*
     If it is a cash offer or possible cash offer, state "N/A" YES
If YES, specify which:
Melrose industries plc

*2.         POSITIONS OF THE PERSON MAKING THE DISCLOSURE*

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

*(a)        Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)*

*Class of relevant security:*

* * *10p ordinary (GB0030646508)*
* *

* * *Interests* *Short positions*
* * *Number* *%* *Number* *%*
*(1) Relevant securities owned and/or controlled:* * * * * * * * *
*(2) Cash-settled derivatives:*

* * *3,500,000* *0.204* *3,500,000* *0.204*
*(3) Stock-settled derivatives (including options) and agreements to purchase/sell:* * * * * * * * *
* *

*     TOTAL:* *3,500,000* *0.204* *3,500,000* *0.204*

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

*(b)        Rights to subscribe for new securities (including directors' and other employee options)*

*Class of relevant security in relation to which subscription right exists:* * *
*Details, including nature of the rights concerned and relevant percentages:* * *

*3.         DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE*

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

*(a)        Purchases and sales*

*Class of relevant security* *Purchase/sale*

* * *Number of securities* *Price per unit*
* * * *

* * * * * *

*(b)        Cash-settled derivative transactions*

*Class of relevant security* *Product description*
e.g. CFD *Nature of dealing*
e.g. opening/closing a long/short position, increasing/reducing a long/short position *Number of reference securities* *Price per unit*
10p ordinary CFD opening a long position 3,500,000 GBP 4.32
10p ordinary CFD opening a short position 3,500,000 GBP 4.32

*(c)        Stock-settled derivative transactions (including options)*

*(i)         Writing, selling, purchasing or varying*

*Class of relevant security* *Product description *e.g. call option *Writing, purchasing, selling, varying etc.* *Number of securities to which option relates* *Exercise price per unit* *Type*
e.g. American, European etc. *Expiry date* *Option money paid/ received per unit*
               

*(ii)        Exercise*

*Class of relevant security* *Product description*
e.g. call option *Exercising/ exercised against* *Number of securities* *Exercise price per unit*
* * * * * * * * * *

* *

*(d)        Other dealings (including subscribing for new securities)*

*Class of relevant security* *Nature of dealing*
e.g. subscription, conversion *Details* *Price per unit (if applicable)*
* * * *

* * * * * *

*4.         OTHER INFORMATION*

*(a)        Indemnity and other dealing arrangements*

*Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:*
Irrevocable commitments and letters of intent should not be included.  If there are no such agreements, arrangements or understandings, state "none"
* *

* *

* *

*(b)        Agreements, arrangements or understandings relating to options or derivatives*

*Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:*
*(i)  the voting rights of any relevant securities under any option; or *
*(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:*
If there are no such agreements, arrangements or understandings, state "none"
* *

* *

* *

*(c)        Attachments*

*Is a Supplemental Form 8 (Open Positions) attached?* NO

*Date of disclosure:* *16 March 2018*

* *
*Contact name:* *Janine Frederick *
*Telephone number:* *02077584420*

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk. Reported by GlobeNewswire 1 hour ago.

ALBANY, New York, March 16, 2018 (GLOBE NEWSWIRE) -- The need of organizations to modify their business models in order to incorporate frequently altering regulations and changes in the demand has fueled the demand for *personal protective equipment* across the world, states Transparency Market Research (TMR) in a new research report. The leading vendors of personal protective equipment are focusing aggressively on product innovation to strengthen their position, along with involving into strategic partnerships to expand their business. 3M Co., Ansell Ltd., MSA SAFETY, National Safety Apparel, Kimberly-Clark Corp., National Safety Apparel, Uvex Safety Group, COFRA Holding AG, Honeywell Safety Products, Avon Rubber, and Rock Fall Ltd. are some of the prominent personal protective equipment providers across the world, notes the market study.

As per the report, the opportunity in the global personal protective equipment market was worth US$40.40 bn in 2016. The market is estimated to expand at a CAGR of 7.0% during the period from 2017 to 2025 and reach a value of US$72.08 bn by the end of the period of the forecast. The demand for personal protective equipment is comparatively higher in the manufacturing industry. Researchers anticipate this scenario to stay same in years to come. Fall protection equipment are the most valued products in this market and are expected to remain so over the next few years. Geographically, North America led the worldwide market for personal protective equipment in 2016 with a share of 38%. The extensive uptake of PPE across various industries in this region is expected to ensure the dominance of North America market for personal protective equipment over the forthcoming years, reports the research study.

*Download PDF Brochure for Research Insights at *https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=842

*Rapid Rise in Industrialization to Propel Market*

“The global market for personal protective equipment has been gaining substantially from the rapid industrialization,” says a TMR analyst. The significant rise in the manufacturing and the transportation industries and the increasing awareness among people regarding personal safety are driving the growth of this market considerably. The rising implementation of strict rules and regulations for work place safety by various governments are also propelling this market to great extents.

Going forward, the demand for personal protective equipment is likely to increase tremendously in the industrial sector in the near future. Products, such as hand protection equipment, fall protection equipment, and protective clothing are expected to find high usage in the industrial sector over the next few years, reflecting greatly on the overall market, states the research report.

*View Report TOC at* https://www.transparencymarketresearch.com/report-toc/842

*Price Volatility of Raw Materials to Hamper Growth*

On the whole, the current performance of worldwide market for personal protective equipment points towards its bright future. However, the volatility in the prices of raw materials required for product manufacturing may hamper the market’s growth over the coming years. Apart from this, the escalating automation in the industrial sector and the availability of inexpensive alternatives may also create hindrance in the steady rise of this market in the near future, notes the market study.

The review is based on a report by Transparency Market Research (TMR), titled “*Personal Protective Equipment Market (Product Type - Eye and Face Protection, Head Protection, Hearing Protection, Protective Clothing, Respiratory Protection, Professional Footwear, Fall Protection, and Hand Protection; Application - Construction, Manufacturing, Oil & Gas, Chemicals, Food, Pharmaceuticals, Transportation, and Healthcare) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025*.”

*Browse Press Release at* https://www.transparencymarketresearch.com/pressrelease/personal-protective-equipment.htm

*Key Takeaways*

· The demand for personal protective equipment is comparatively higher in the manufacturing industry.
· North America led the worldwide market for personal protective equipment in 2016 with a share of 38%.

The global personal protective equipment market is segmented into:*By Product Type*

· Eye and Face Protection
· Head Protection
· Hearing Protection
· Protective Clothing
· Respiratory Protection
· Professional Footwear
· Fall Protection
· Hand Protection
· Other

*By Application*

· Construction
· Manufacturing
· Oil & Gas
· Chemicals
· Food
· Pharmaceuticals
· Transportation
· Healthcare
· Others

*By Geography*

· North America
· Europe
· Asia Pacific
· Middle East and Africa
· South America

*About Us*

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

*Contact Us*

Mr. Atil Chaudhari
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
Research Blog: http://www.techyounme.com/ Reported by GlobeNewswire 1 hour ago.

HONG KONG, March 16, 2018 (GLOBE NEWSWIRE) --

Bonso Electronics International, Inc. (NASDAQ:BNSO) today announced the results of the Company’s Annual General Meeting of Shareholders (the “AGM”) held on March 7, 2018, in Fu Yong, Shenzhen, Guangdong, Peoples Republic of China.At the AGM, the shareholders approved and ratified (i) the appointment of Mr. Anthony So, Mr. Andrew So, Mr. Albert So, Mr. Kim Wah Chung, Mr. Woo Ping Fok, and Mr. Henry F. Schlueter as members of the Board of Directors to serve for the ensuing year; and (ii) the appointment of Moore Stephens CPA Limited, as Bonso’s independent registered public accounting firm for the fiscal year ending March 31, 2018.

About Bonso Electronics

Bonso Electronics designs, develops, manufactures, assembles and markets a comprehensive line of electronic scales, weighing instruments, and health care products. Bonso products are manufactured in the People's Republic of China for customers primarily located in North America and Europe. Company services include product design and prototyping, production tooling, procurement of components, total quality management, and just-in-time delivery. Bonso also independently designs and develops electronic products for private label markets. For further information, visit the company's web site at http://www.bonso.com.

This news release includes forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Forward looking statements may be identified by such words or phrases as "should,'' "intends,'' "is subject to,'' "expects,'' "will,'' "continue,'' "anticipate,'' "estimated,'' "projected,'' "may,'' "I or we believe,'' "future prospects,'' or similar expressions. Forward-looking statements made in this press release, which relate to the demand for our products, among other things, involve known and unknown risks and uncertainties that may cause the actual results to differ materially from those expected and stated in this announcement. We undertake no obligation to update “forward-looking” statements.

For more information please contact:

Albert So
Chief Financial Officer and Secretary
Tel: 852 2605 5822
Fax: 852 2691 1724 Reported by GlobeNewswire 1 hour ago.

*FORM 8.3*

*PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY *
*A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE*
*Rule 8.3 of the Takeover Code (the "Code")*

*1.         KEY INFORMATION*

*(a) Full name of discloser:* OZ Management LP and
Och-Ziff Management Europe Ltd
*(b) Owner or controller of interests and short positions disclosed, if different from 1(a):*
     The naming of nominee or vehicle companies is insufficient.  For a trust, the trustee(s), settlor and beneficiaries must be named.  
*(c) Name of offeror/offeree in relation to whose relevant securities this form relates:*
     Use a separate form for each offeror/offeree GVC Holdings plc
*(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:*  
*(e) Date position held/dealing undertaken:*
     For an opening position disclosure, state the latest practicable date prior to the disclosure 15 March 2018
*(f)  In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?*
     If it is a cash offer or possible cash offer, state "N/A" Yes
If YES, specify which:
Ladbrokes Coral Group plc

*2.         POSITIONS OF THE PERSON MAKING THE DISCLOSURE*

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

*(a)        Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)*

*Class of relevant security:*

* * *Euro 0.01 ordinary (IM00B5VQMV65)*
* *

* * *Interests* *Short positions*
* * *Number* *%* *Number* *%*
*(1) Relevant securities owned and/or controlled:* * * * * * * * *
*(2) Cash-settled derivatives:*

* * *6,120,629* *2.016* *1,274,942* *0.420*
*(3) Stock-settled derivatives (including options) and agreements to purchase/sell:* * * * * * * * *
* *

*     TOTAL:* *6,120,629* *2.016* *1,274,942* *0.420*

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

*(b)        Rights to subscribe for new securities (including directors' and other employee options)*

*Class of relevant security in relation to which subscription right exists:* * *
*Details, including nature of the rights concerned and relevant percentages:* * *

*3.         DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE*

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

*(a)        Purchases and sales*

*Class of relevant security* *Purchase/sale*

* * *Number of securities* *Price per unit*
* * * *

* * * * * *

*(b)        Cash-settled derivative transactions*

*Class of relevant security* *Product description*
e.g. CFD *Nature of dealing*
e.g. opening/closing a long/short position, increasing/reducing a long/short position *Number of reference securities* *Price per unit*
Euro 0.01 ordinary CFD Increasing a short position 50,000 GBP 9.50

*(c)        Stock-settled derivative transactions (including options)*

*(i)         Writing, selling, purchasing or varying*

*Class of relevant security* *Product description *e.g. call option *Writing, purchasing, selling, varying etc.* *Number of securities to which option relates* *Exercise price per unit* *Type*
e.g. American, European etc. *Expiry date* *Option money paid/ received per unit*
               

*(ii)        Exercise*

*Class of relevant security* *Product description*
e.g. call option *Exercising/ exercised against* *Number of securities* *Exercise price per unit*
* * * * * * * * * *

* *

*(d)        Other dealings (including subscribing for new securities)*

*Class of relevant security* *Nature of dealing*
e.g. subscription, conversion *Details* *Price per unit (if applicable)*
* * * *

* * * * * *

*4.         OTHER INFORMATION*

*(a)        Indemnity and other dealing arrangements*

*Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:*
Irrevocable commitments and letters of intent should not be included.  If there are no such agreements, arrangements or understandings, state "none"
* *

* *

* *

*(b)        Agreements, arrangements or understandings relating to options or derivatives*

*Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:*
*(i)  the voting rights of any relevant securities under any option; or *
*(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:*
If there are no such agreements, arrangements or understandings, state "none"
* *

* *

* *

*(c)        Attachments*

*Is a Supplemental Form 8 (Open Positions) attached?* NO

*Date of disclosure:* *16 March 2018*

* *
*Contact name:* *Janine Frederick *
*Telephone number:* *02077584420*

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk. Reported by GlobeNewswire 1 hour ago.

Valley Cottage – NY, March 16, 2018 (GLOBE NEWSWIRE) -- Meat substitutes are considered as being at the apex, with regards to innovation of food. There is no indication that the consumers will recoil from meat any time soon. However, there is increase in the demand for flexibility requirements in the diet. Controlling meat consumption is regarded as a method of flexibility. Apart from health-associated factors, sustainability and considerations are also impelling this movement, especially amongst the women. There is increase in the demand for meat substitutes mainly due to increasing health concerns such as diabetes and obesity.

The global meat substitutes market is expected to grow due to health benefits such as general wellbeing and weight loss. Increasing adoption level of meat substitutes is influencing the manufacturers to develop and innovate the meat substitutes’ product lines, which eventually contributes considerably towards the growth of the global market for meat substitutes. In addition, perceived environmental and social concerns related to excessive consumption of meat, for instance, religious limitations as well as carbon footprint of meat production, has further directed consumers to decrease meat consumption and go for its substitutes.

Noteworthy findings from the report indicates that the global market for meat substitutes will upsurge at an evaluated 5.8% CAGR over the forecast period, 2017-2026. The report also expects that by 2026-end, meat substitutes worth US$ 7,067.6Mn will be sold across the globe.

*Request to View Sample Report* - https://www.futuremarketinsights.com/reports/sample/REP-GB-899

*Meat Substitutes That Are Soy-Based to Create Opportunities for Expansion of Global Market*

Meat substitute products that are soy-based holds the potential for contributing the largest share in the market, followed by mycoprotein, through 2026. This is due to the fact that soy proteins are cost-efficient and dependable substitutes for meat and possesses the largest amount of protein, compared to various other meat substitutes. Meat substitutes that are soy-based also hold the capacity to be formed, in a way that it can represent the organoleptic features of meat products. Soy hot dogs, soy chicken, soy bacon, soy turkey and soy burger are a few prevalent soy-based food products.

Frozen meat substitutes amongst the category type products accounts for lion’s share in the market through 2026. The increasing demand for convenience foods due to rising income level of consumers, is considered as one of the important factors that is fuelling the frozen meat substitutes market. Major countries like India and China are significantly contributing towards the expansion of the global frozen meat substitutes market.

*To view TOC of this report is available upon request @:* https://www.futuremarketinsights.com/askus/rep-gb-899

*Notable Highlights from the Report on Meat Substitutes Market for Forecast Period, 2017-2026*

· Europe will continue to dominate in the global market for meat substitutes. The market is fuelled with the increasing health-conscious consumers, rising incidences of conditions and diseases such as high-blood pressure, diabetes and constipation.

· Based on category, frozen meat substitutes holds the lion’s share in the global market for meat substitutes, followed by refrigerated meat substitutes. Market for frozen meat substitutes is gaining traction owing to variable purchasing patterns and shifting consumer preferences from small grocery shops to super and hypermarkets, especially in the emerging economies like Brazil, China and India.

· Textured vegetable protein accounts for largest share in the market, based on product type, due to the fact that they hold higher protein content and are easily available compared to other products.

· Meat substitutes based on soy account for largest share in the market, based on source type, followed by mycoprotein. This is owing to the fact that consumers on a larger basis are preferring meat products that are based on soy, as it holds high protein content compared to other sources. This has led to increase of demand for soy in meat substitutes industry.

Important market players sketched by the report is inclusive of Amys Kitchen Inc., Cauldron Foods, Meatless B.V., Vbites Food, Ltd., MGP Ingredients Inc., The Nisshin OilliO Group, DuPont, Beyond Meat, Garden Protein International, Inc., Quorn Foods, Morningstar Farms, Sonic Biochem Extractions Limited and ADM.

*Global Meat Substitutes Market Market Report is available @ US$ 5000*

*More from FMI’s Food and Beverages Market Intelligence:*

· *Essential Fatty Acids Market *Segmentation By Product - Omega-3 Fatty Acid (ALA, DHA, EPA), Omega-6 Fatty Acid(LA, ARA), Omega-7 Fatty Acid, Omega-9 Fatty Acid; By Application - Dietary Supplement, Infant Formula, Pharmaceutical, Food and Beverages, Animal Food and Feed, Cosmetics; By Source – Marine (Algal and Fungus Oil, Fish Oil, Krill Oil), Plant (Chia Seed Oil, Flax Seed Oil, Others), Dairy Products; By Form – Oil, Syrup, Powder, Others: https://www.futuremarketinsights.com/reports/essential-fatty-acids-market 

· *Floral Flavour Market *Segmentation by End Use – Food ( Dairy (Yogurt, Ice-cream, Others ), Bakery(Sponge Cakes, Cookies, Breads ), Confectionary, Snacks, Fats and Oils), Beverages (Alcoholic, Non-alcoholic ( Herbal Teas, Soft Drinks, Health Drinks, Flavoured Water)), Others (Cigars, Tobacco, Pharmaceuticals, etc.); By Raw Material – Hibiscus, Lavender, Neroli/ Orange Flower, Rose, Elderflower, Jasmine, Cherry Blossom, Chamomile, Violette; By Product Type – Natural, Organic, Artificial: https://www.futuremarketinsights.com/reports/floral-flavors-market

· *Europe Malt Extract Market *Segmentation By Application – Bakery, Confectionary, Beverages (Alcoholic, Non-Alcoholic), Animal Feed, Pharmaceuticals; By Source – Barley, Wheat, Rice, Rye; By Product Form – Dry, Liquid; By Product Type – Standard, Speciality: https://www.futuremarketinsights.com/reports/europe-malt-extract-market

*About Us*

Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centres in the U.S. and India.

FMI’s research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customised and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure our clients prepare for the evolving needs of their consumers.

*Contact Us*

Mr. Sudip Saha
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
T (UK): + 44 (0) 20 7692 8790
Sales: sales@futuremarketinsights.com
Press Office: Press@futuremrketinsights.com
FMI Blog: http://www.fmiblog.com/
Website: www.futuremarketinsights.com Reported by GlobeNewswire 1 hour ago.

New York, March 16, 2018 (GLOBE NEWSWIRE) -- Increasing demand for white chocolates in food and beverage industry and cosmetics sector continues to be a key driving factor for the growth of the market. The various features of white chocolate, such as skin hydration, rich, variable textures, and superior taste is driving demand for white chocolates in the F&B, and cosmetics industry.

Key market players such as Mars Incorporated, GCPPL Ltd., Nestle SA, Ghirardelli Chocolate Co., Mondelez International, Chocolatiers (UK) Ltd, Blommer Chocolate Company, Unilever, Agostoni Chocolate, Barry Callebaut, Ferrero and The Hershey Company are focusing on product innovation and expansion to consolidate their position. The report projects that revenues from global white chocolate market  will increase at a remarkable 6.5% CAGR during the projection period, 2017-2026. By 2026-end, the market is expected to surpass a valuation of over US$ 23 Bn.

*Global White Chocolate Market Research Report Overview @ *https://www.persistencemarketresearch.com/market-research/white-chocolate-market.asp

Increasing flexibility and multiple health benefits from white chocolates is driving the production sales of global market for white chocolate. There is rapid increase in number of chocolate manufacturing industries considering the rising consumer needs. Consumer preferences have been shifting from milk and dark chocolates to white chocolates which again is creating opportunities for manufacturers. Sustainable, healthy, premium and indulgent will be the significant trends driving white chocolate industry in the forthcoming years.

Going premium can stimulate the demand for white chocolates and providing origin on the label of the chocolate is expected to attract more customer attention. According to the current scenario, consumers are also prepared to pay extra in order to obtain premium products. Combining several textures and flavors in one white chocolate bar is an emerging trend for the confectioners for the purpose of creating indulgent products.

*Request Sample Report@* https://www.persistencemarketresearch.com/samples/22501

*North America’s White Chocolate Market to Hold Lion’s Share in The Global Market by Growing at A Remarkable 7.6% CAGR*

Manufacturers in North America have been working on making more flexible products, especially in the US. There is increasing demand for white chocolate bars amongst the consumers in US as well as Canada. Additionally, white chocolate business contributes significantly towards the financial growth of the region due to increasing awareness amongst the populace regarding the benefits of white chocolate consumption.

Europe and APEJ are expected to emerge as lucrative markets for white chocolate in the forthcoming years. Incorporation of cocoa butter is more in white chocolates of APEJ and Europe. Besides, Europeans also consider low sugar content in their confectionery, as a result of rising health-conscious consumers.

*Download and View Report TOC, Figures and Tables @ *https://www.persistencemarketresearch.com/market-research/white-chocolate-market/toc

*Food & Beverage Industry to Drive in Significant Revenues for the Global Market*

There is increasing demand for white chocolate flavored products in the food and beverage industry, mainly due to it creamy and elegant taste. The beverage sector, especially in US, is increasing the usage of white chocolate flavored products. However, cosmetics industry is likely to emerge as a profitable sector for white chocolate market in the forthcoming years. Established brands such as Starbucks are making innovative drinks with the combination of white chocolate properties. Pharmaceuticals industry is gradually increasing the usage of white chocolates in the manufacturing of medical-related products, due to increasing awareness amongst the pharmacists and manufacturers in the sector.

Modern trade continues to be a lucrative distribution channel in the global market. This growth is fuelled by several aspects such as comfortable and new shopping experience, approach to various types and a wide range of brands, available in one place along with attractive prices.

*Get full Report Now *https://www.persistencemarketresearch.com/checkout/22501

*Persistence Market Research Overview*

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

*Contact Us*Ashwani Bhagat
Persistence Market Research
U.S. Sales Office:
305 Broadway, 7th Floor
New York City, NY 10007
+1-646-568-7751
United States
USA - Canada Toll-Free: 800-961-0353
Email: sales@persistencemarketresearch.com
PMR Latest News: https://www.persistencemarketresearch.com/news Reported by GlobeNewswire 1 hour ago.

VANCOUVER, British Columbia, March 16, 2018 (GLOBE NEWSWIRE) -- *Avrupa Minerals Ltd. *(TSXV:AVU) (OTC:AVPMF) (FRANKFURT:8AM)* *is pleased to announce that the financing it has arranged to raise $500,000 by way of a private placement of 6.25 million units at $0.08 per unit is fully subscribed and will close shortly.The funds will be used for working capital and exploration in Portugal and Kosovo. Avrupa is in the process of completing the final agreements for the three properties in Portugal – Alvalade, Marateca and Mertola. Significant work programs will be announced for these properties upon completion of the final agreements relating to the March 5, 2018 announcement.

Each unit (a “Unit) is comprised of one common share and a common share purchase warrant which entitles the holder to purchase one common share at a price of $0.12 for a period of two years from closing of the offering.

Avrupa has also granted stock options to its directors, officers, employees and consultants exercisable to acquire 1.8 million common shares at $0.10 per share for a period of five years.

*Avrupa Minerals Ltd.* is a growth-oriented junior exploration and development company focused on discovery, using a prospect generator model, of valuable mineral deposits in politically stable and prospective regions of Europe, including Portugal, Kosovo, and Germany.

The Company currently holds eight exploration licenses in three European countries, including five in Portugal covering 2,911 km^2, two in Kosovo covering 47 km^2, and one in Germany covering 307 km^2.  Avrupa now has six active option and joint ventures, five in Portugal and one in Kosovo, including:

· The *Alvalade, Marateca and Mertola* properties with an international mining company on the Iberian Pyrite Belt in southern Portugal.

· The* Alvito Option Agreement* with OZ Minerals Limited covering one license in the Ossa Morena Zone in southern Portugal, for IOCG deposits;

· The *Covas JV*, with Blackheath Resources, covering one license in northern Portugal, for intrusion-related W deposits; and

· Avrupa’s partner at the *Slivovo Gold Project* in Kosovo is fully funding the program, allowing Avrupa to dilute its ownership in the JV operating company Peshter Mining JSC.  If AVU ownership goes below 10%, the interest in the project converts to a 2% NSR.

For additional information, contact Avrupa Minerals Ltd. at 1-604-687-3520 or visit our website at www.avrupaminerals.com.

On behalf of the Board,

**“Paul W. Kuhn”**

                                               
Paul W. Kuhn, President & Director

This news release was prepared by Company management, who take full responsibility for its content.  Paul W. Kuhn, President and CEO of Avrupa Minerals, a Licensed Professional Geologist and a Registered Member of the Society of Mining Engineers, is a Qualified Person as defined by National Instrument 43-101 of the Canadian Securities Administrators.  He has reviewed the technical disclosure in this release.  Mr. Kuhn, the QP, has not only reviewed, but prepared and supervised the preparation or approval of the scientific and technical content in the news release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Reported by GlobeNewswire 44 minutes ago.

VANCOUVER, British Columbia, March 16, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – PreveCeutical Medical Inc. (the “*Company*” or “*PreveCeutical*”) (CSE:PREV) (OTCQB:PRVCF) (FSE:18H), announces the incorporation of its first Australian wholly-owned subsidiary, PreveCeutical (Australia) Pty Ltd, as part of an expansion of the Company’s business in Brisbane, Australia. PreveCeutical’s new Australian team, led by Director of International Operations, Dr. Maher Khaled, will work closely with the Company’s Chief Research Officer, Dr. Harry Parekh, to advance the development of the Company’s therapeutic technologies. The decision to incorporate the Company’s first subsidiary in Australia was influenced by Australia’s strong foundation of academic and clinical research, as well as the Australian government’s commitment to supporting innovation through a range of programs and incentives. Such incentives include the research and development (R&D) tax incentive, whereby the Australian government encourages companies to engage in R&D benefiting Australia by providing a tax offset for eligible R&D activities. The current annual refundable tax offset under the program is 43.5%.

Commenting on the announcement, Dr. Khaled stated, “Establishing a business presence in Australia will allow PreveCeutical to better access expertise and partnerships for its drug development programs. Many specialized Australian hospitals have strong clinical trial capabilities as well as the diverse patient populations needed for the range of products PreveCeutical is currently developing. Combined with Australia’s favourable regulatory regime for clinical trials, these benefits make Australia an attractive location for product development in preparation for commercialisation through the Company’s established North American networks”.

*Australian Subsidiary Team*

Management of the Company’s Australian subsidiary includes the following individuals:

*Stephen Van Deventer – Chairman and Director*
Mr. Van Deventer is an experienced businessman and corporate director. Specialising in international corporate relations and business development over the last twenty-five years, Mr. Van Deventer has focused on launching small to medium-sized companies into the public markets in Canada, the United States and Europe. He has also owned and operated private businesses.

*Maher Khaled – PhD, LLB, BSc – Chief Executive Officer, Secretary and Director*
Dr. Khaled has spent over a decade commercializing therapeutic and diagnostic technologies developed at the University of Queensland and the University of Cambridge, United Kingdom, while working at UniQuest Pty Ltd. Prior to his work at UniQuest, Dr. Khaled was an investment manager at Cambridge Enterprise Seed Funds. While at Cambridge, Dr. Khaled directed the investment of seed capital in start-up companies, and in some of which also held directorships. He also advised pharmaceutical and medical device companies on strategic and operational issues while working at McKinsey & Company’s London office. Dr. Khaled holds a PhD in Biotechnology, as well as a Bachelor of Laws (LLB) and a BSc in Biomedical Science, all from the University of Queensland. Dr. Khaled is an admitted solicitor of the Supreme Court of Queensland*.*

*Kimberly Van Deventer – Director*
Ms. Van Deventer is an entrepreneur with a successful track record of accomplishment that she has brought to PreveCeutical. Motivated and determined, she was ranked the third highest grossing female business owner in British Columbia, Canada in 2009. Ms. Van Deventer is a driving force behind PreveCeutical and unwavering in her commitment to raising awareness about health and disease prevention.

*Shabira Rajan, MBA, CPA, CGA – Chief Financial Officer*
Ms. Rajan is a senior financial executive with over 20 years of experience, leading the financial discipline for successful businesses in both private and public sectors. She has a track record of providing leadership for strategic value creation and continuous improvement, as well as providing effective direction to organisations on issues relating to corporate governance, financial oversight and risk management. One of her past leadership roles was that of Director of Finance at Canada Line Rapid Transit Inc., which planned and constructed a $2 billion rapid transit system in metro-Vancouver, on time and within budget.

*About PreveCeutical*

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.

PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical^™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

PreveCeutical sells CELLB9^®, an Immune System Booster. CELLB9^® is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. This product is available on the Company’s website.

For more information about PreveCeutical, please visit www.PreveCeutical.com, follow us on Twitter: http://twitter.com/PreveCeuticals and Facebook: www.facebook.com/PreveCeutical.

*On Behalf of the Board of Directors*

“Stephen Van Deventer”
Chairman & CEO

*For further information, please contact:*

Deanna Kress
Director of Corporate Communications & Investor Relations
+1-778-999-6063
deanna@PreveCeutical.com

*Corporate Communications Contact: *
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

*Forward-Looking Statements:*

This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations and orientations regarding the future including the Company’s anticipated business plans, and the prospect of its ability and success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as “pro forma”, “plans”, “expects”, “may”, “should”, “budget”, “schedules”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, “potential” or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Actual results could differ from those projected in any forward-looking statements due to numerous factors including risks and uncertainties relating to the inability of the Company, to, among other things, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities, commercialise therapeutic and diagnostic technologies, pursue business partnerships, complete its research programs as planned, qualify for government tax benefits or programs and obtain the financing required to carry out its planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology or pharmaceutical industry, may also adversely affect the future results or performance of the Company. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although the Company believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-to-time. These reports and the Company’s filings are available at www.sedar.com.

Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements. Reported by GlobeNewswire 44 minutes ago.

NEW YORK, March 16, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces financial results for the twelve months ended December 31, 2017.Highlights from the fourth quarter of 2017 and recent weeks include:

· Revenue from European sales for 2017 increased 35% to $2.7 million from $2.0 million in 2016;
· Satisfaction of all obligations under the privately placed senior secured convertible notes issued to two institutional investors in June 2016;
· Completed a $5.0 million capital raise in February 2018;
· Modified the Special Protocol Agreement (SPA) with the U.S. Food and Drug Administration (FDA) for the Company’s Phase 3 clinical trial of Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) to treat patients with hepatic dominant ocular melanoma (OM);
· Announced that the independent Data Safety Monitoring Board (DSMB) of the Phase 3 FOCUS clinical trial recommended that the study continue without modification; Reported the 500th CHEMOSAT treatment in Europe;
· Announced results from a multi-center analysis of Delcath’s Percutaneous Hepatic Perfusion (PHP) therapy in the peer-reviewed Journal of Surgical Oncology; largest data set outside of clinical trial showed manageable toxicity and overall median overall survival of 15.3 months, and;  
· Secured a commercial supply of melphalan through an agreement with Tillomed Laboratories for use with the company’s CHEMOSAT® Delivery System for Melphalan, where it is marketed in Europe for the treatment of a wide range of cancers of the liver. 

*Management Commentary*

“For much of the second half of 2017 and recent weeks, our focus has been on easing the cash constraints and other restrictions related to our capital structure,” said Jennifer K. Simpson, Ph.D., MSN, CRNP President and CEO of Delcath. “These limitations necessitated a series of transactions during the second half of 2017 and the early weeks of 2018 that have permitted us to exit our 2016 Convertible Note, invest in our clinical development program, and advance our commercialization efforts for CHEMOSAT in Europe.   We continue to work to resolve the remaining issues and to secure new equity financing under less dilutive terms to execute our plan and create value for our shareholders.”

"Despite cash constraints, total revenues for fiscal year 2017 increased 35% over the prior year, continuing the steady growth in our core European markets.  This growth was supported by the establishment of ZE diagnostic-related (DRG) reimbursement for CHEMOSAT in Germany, which we are leveraging to obtain market access and reimbursement in other regions such as the United Kingdom and the Netherlands. In the Netherlands, Dutch Health Authorities have included CHEMOSAT treatment in their published guidelines for OM liver metastases. We are hopeful that inclusion in the national guidelines and the support of clinicians treating patients with CHEMOSAT will support an application for reimbursement in this market. Since launching CHEMOSAT in Europe, over 500 commercial CHEMOSAT procedures have been performed.

“In our clinical development program, we achieved an important milestone in December 2017 when the independent DSMB for our Phase 3 FOCUS clinical trial for patients with hepatic dominant OM completed a pre-specified review of safety data and recommended that the study continue without modification. This confirms our own observations of the improvements in the safety profile of PHP therapy based on prior research and our commercial experience with CHEMOSAT in Europe. We were also happy to announce a SPA modification agreement with the FDA to revise the FOCUS trial’s eligibility criteria to permit a greater extent of extra-hepatic disease by removing the size restriction, number and location of extra-hepatic lesions, in conjunction with a treatment plan for the extra-hepatic metastases. We requested this protocol modification to improve patient access to this important clinical trial for appropriately selected patients. In an ultra-orphan indication like OM, striking the appropriate balance between eligibility criteria and patient access can be a challenge. We are pleased that the FDA agreed to this modification, and hope that once approved by the European Competent Authorities, ethics boards and institutional review boards of our participating clinical trial sites, this protocol modification will help accelerate enrollment in this registration trial.

“Enrollment in our FOCUS Phase 3 Trial has been slower than anticipated, and our ability to take proactive steps to support enrollment was limited by the cash constraints we operated under in 2017. With the rollout of the SPA protocol modification to participating centers underway, we hope to accelerate enrollment in 2018 and expect to update our enrollment projections in the second half of this year. Any impact on enrollment from the SPA modification is not expected to be immediate, and it is unlikely that enrollment for this trial will be completed in time to submit an NDA to the FDA in 2019.

“For our pivotal trial in intrahepatic cholangiocarcinoma (ICC), we continue to work with potential trial sites with a view to opening the trial in the first half of 2018.  Our ICC pivotal trial is based on the prior work done in our Phase 2 trial program in hepatocellular carcinoma (HCC) and ICC, which had the objective of identifying an efficacy signal worthy of further clinical investigation. This objective was met by the retrospective data collection performed by European investigators last year, which informed our development path for ICC. We have closed enrollment in the Phase 2 trials to devote available resources to the FOCUS Trial and the planned ICC pivotal trial.

"Though the recent months have been financially difficult, we remain committed to advancing our clinical and commercial programs. We are continuously working to improve our ability to operate so we can realize the potential of PHP therapy and return value to our shareholders," concluded Dr. Simpson.

*2017 Financial Results*

Total revenue for the year ended December 31, 2017 of $2.7 million was an increase of 35% when compared to the $2.0 million total for 2016.  The increase is the result of greater product sales in Europe in 2017 as Delcath continued to see increased market acceptance of its product, particularly in Germany where the establishment of the ZE code contributed to an increase in treatments.

Research and development (R&D) expenses for 2017 increased to $10.5 million from $8.4 million for the prior year, largely as a result of costs associated with the Company’s ongoing Phase 3 FOCUS Trial. Selling, general and administrative expenses for 2017 increased to $9.7 million from $9.4 million in 2016, primarily due to an increase in Delaware corporate taxes, independent audit fees, and costs associated with the Company’s efforts to secure approval for a reverse stock split. 
  
For the year ended December 31, 2017, derivative instrument income increased to $15.1 million from $12.8 million for the year ended December 31, 2016. The increase of $2.3 million is due to the issuance of the November 2017 warrants and the subsequent mark-to-market adjustment at December 31, 2017.

The Company had a net loss for the year ended December 31, 2017 of $45.1 million, an increase of $27.1 million, or 151.1%, compared to the net loss of $18.0 million for the same period in 2016.  Approximately $2.3 million is related to an increase in operating expenses primarily related to increased investment in clinical trial initiatives. The balance of the increase is related to several non-cash items, including a $7.4 million increase in interest expense primarily related to the amortization of debt discounts and a $29.9 million loss on the settlement of the convertible note debt, which was partially offset by a $2.3 million change in the fair value of the warrant liability and a $9.6 million gain on the extinguishment of the June 2016 Series C Warrants.

The 2016 net loss included a $14.3 million increase in interest expense primarily related to the amortization of debt discounts and a $1.4 million increase in operating expenses primarily related to increased investment in clinical trial initiatives. This was offset by a $12.2 million change in the fair value of the warrant liability, a non-cash item, and a $0.2 million improvement in gross profit due to increased sales.

*Balance Sheet Highlights*

As of December 31, 2017, Delcath had cash and cash equivalents of $4.0 million, compared with $4.4 million as of December 31, 2016.  During 2017 the Company used $15.4 million of cash to fund operating activities.

On February 9, 2018, the Company closed a registered offering of 212.0 million shares of common stock, 38.0 million pre-funded warrants to purchase 38.0 million shares of common stock and warrants to purchase an aggregate of 500.0 million shares of common stock for total gross proceeds of approximately $5.0 million.

Delcath believes it has sufficient capital and access to committed capital to fund its operating activities through May of 2018.

*About Delcath Systems*

Delcath Systems, Inc. is an interventional oncology Company focused on the treatment of primary and metastatic liver cancers. Our investigational product – Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) – is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. We have commenced a global Phase 3 FOCUS clinical trial for Patients with Hepatic Dominant Ocular Melanoma (OM) and plan to initiate a Registration trial for intrahepatic cholangiocarcinoma (ICC). Melphalan/HDS has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S.  In Europe, our system has been commercially available since 2012 under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT), where it has been used at major medical centers to treat a wide range of cancers of the liver.

*Forward Looking Statements*

Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to:  the timing and results of the Company’s  clinical trials including without limitation the OM and ICC  clinical trial programs,  timely enrollment and treatment of patients in the global Phase 3 OM clinical trial, IRB or ethics committee clearance of the  Phase 3 OM and ICC Registration trial  protocols from  participating sites and the timing of site activation and subject enrollment in each trial, the impact of the presentations at major medical conferences and future clinical results consistent with the data presented, approval of Individual Funding Requests for reimbursement of the CHEMOSAT procedure, the impact, if any  of ZE reimbursement on potential CHEMOSAT product use and sales in Germany, clinical adoption, use and resulting sales, if any, for the CHEMOSAT system to deliver and filter melphalan in Europe including the key markets of Germany and the UK, the Company’s ability to successfully commercialize the Melphalan HDS/CHEMOSAT system and the potential of the Melphalan HDS/CHEMOSAT system as a treatment for patients with primary and metastatic disease in the liver, our ability to obtain reimbursement for the CHEMOSAT system in various markets,, approval of the current or future Melphalan HDS/CHEMOSAT system for delivery and filtration of melphalan or other chemotherapeutic agents for various indications in the U.S. and/or in foreign markets, actions by the FDA or other foreign regulatory agencies, the Company’s ability to successfully enter into strategic partnership and distribution arrangements in foreign markets and the timing and revenue, if any, of the same, uncertainties relating to the timing and results of research and development projects, and uncertainties regarding the Company’s ability to obtain financial and other resources for any research, development, clinical trials and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

*Contact:*
Delcath Investor Relations
Email: investorrelations@delcath.com

--Financial Tables to Follow--

 
*DELCATH SYSTEMS, INC.*
Consolidated Statements of Operations and Comprehensive Loss
for the twelve months ended December 31, 2017, 2016 and 2015
(in thousands, except share data)
             
    *Year ended December 31,*
      *2017*       *2016*       *2015*  
Revenue   $   2,715     $   1,992     $   1,747  
Cost of goods sold       (701 )       (550 )       (462 )
Gross profit       2,014         1,442         1,285  
             
Operating expenses:            
Selling, general and administrative expenses       9,684         9,434         10,009  
Research and development expenses       10,495         8,448         6,486  
Total operating expenses       20,179         17,882         16,495  
Operating loss       (18,165 )       (16,440 )       (15,210 )
Change in fair value of the warrant liability, net       15,103         12,780         564  
Gain on warrant extinguishment       9,613         —         —  
Loss on debt settlements and extinguishments       (29,924 )       —         —  
Interest expense       (21,703 )       (14,328 )       (67 )
Other income (expense)       (41 )       17         9  
Net loss   $   (45,117 )   $   (17,971 )   $   (14,704 )
Other comprehensive loss:            
Foreign currency translation adjustments   $   83     $   (33 )   $   (28 )
Comprehensive loss   $   (45,034 )   $   (18,004 )   $   (14,732 )
             
Common share data:            
Basic and diluted loss per share*   $   (6.50 )   $   (3,707 )   $   (5,096 )
             
Weighted average number of basic and diluted shares outstanding*       7,019,316         4,847         2,887  
             
*reflects a one-for-sixteen (1:16) reverse stock split effected on July 21, 2016 and a one-for-three hundred and fifty (1:350) reverse stock split effected on November 6, 2017.
 

 
*DELCATH SYSTEMS, INC.*
 Consolidated Balance Sheets
as of December 31, 2017 and 2016
(in thousands, except share and per share data)
         
    * December 31, *   * December 31, *
      *2017*       *2016*  
*Assets*        
Current assets        
Cash and cash equivalents   $   3,999     $   4,409  
Restricted cash       1,325         27,287  
Accounts receivables, net       317         403  
Inventories       1,248         660  
Prepaid expenses and other current assets       700         698  
Deferred financing costs       —         699  
Total current assets       7,589         34,156  
Property, plant and equipment, net       1,298         1,083  
Total assets   $   8,887     $   35,239  
         
*Liabilities and Stockholders' Equity (Deficit)*        
Current liabilities        
Accounts payable   $   3,846     $   594  
Accrued expenses       3,408         3,407  
Convertible notes payable, net of debt discount       —         13,343  
Warrant liability       560         18,751  
Total current liabilities       7,814         36,095  
Deferred revenue       —         30  
Other non-current liabilities       395         604  
Total liabilities       8,209         36,729  
         
Commitments and contingencies        
         
Stockholders' Equity (Deficit)        
Preferred stock, $.01 par value; 10,000,000 shares authorized; no shares
  issued and outstanding at December 31, 2017 and December 31, 2016,
  respectively       —         —  
Common stock, $.01 par value; 500,000,000 shares authorized; 114,055,137 and
  11,805 shares issued and 114,054,851 and 11,750 shares outstanding
  at December 31, 2017 and December 31, 2016, respectively*       1,141         —  
Additional paid-in capital       324,378         277,790  
Accumulated deficit       (324,832 )       (279,188 )
Treasury stock, at cost; 1 share at December 31, 2017 and December 31, 2016,
  respectively*       (51 )       (51 )
Accumulated other comprehensive loss       42         (41 )
Total stockholders' equity (deficit)       678         (1,490 )
Total liabilities and stockholders' equity (deficit)   $   8,887     $   35,239  
         
*reflects a one-for-sixteen (1:16) reverse stock split effected on July 21, 2016 and a one-for-three hundred and fifty (1:350) reverse stock split effected on November 6, 2017.
  Reported by GlobeNewswire 44 minutes ago.

Garry White, chief investment commentator, looks at the market moving events that have shaped the UK equity markets this week (March 12 to March 16, 2018).

This week, Barbadian singing sensation Rhianna managed to wipe $1bn off the valuation of tech group Snap, the Chinese secured a major cobalt deal to help it produce electric vehicles and Unilever said it would move its base to Rotterdam, which may result in it being excluded from the FTSE 100. The FTSE 100 fell 0.9% over the week by mid-session on Friday.

*Spring statement*

UK Chancellor Philip Hammond says there is “light at the end of the tunnel” for the UK economy as he delivers an upbeat assessment of the outlook. Henry Brennan rounds up the important points here.

*Bond markets*

Markets were hit by the highest levels of volatility recorded in nearly a decade last month, fuelled by better than expected inflation data and a subsequent spike in global bond yields in January. Charles Stanley’s bond analyst Jeremy Spain takes a look at what is going on here.

*Emerging markets*

John Redwood, Charles Stanley’s Chief Global Strategist takes a look at China. He examines the issues around its transition to a higher-value-added economy here and looks at the future after the ruling party changes the rules of President Xi Jinping could rule for life here.

*Energy*

Brent crude prices moved 0.5% lower over the week by mid-session on Friday.

The timetable for the floatation of Saudi Aramco, potentially the world’s largest company, may have slipped into next year according to press reports. Reports also suggested that a delegation of Saudi officials to New York were surprised to find investors were not that interested, especially balking at the $2bn mooted valuation. Garry White looks at the options available for crown Prince Mohammed bin Salman here.

*Mining*

The Chinese made a wise move this week after it signing an agreement with the world’s largest producer of cobalt to take one-third of its production over the next three years. *Glencore* signed the deal with Chinese battery recycler GEM and cobalt is a critical metal in lithium-ion batteries, used in electric vehicles.

*Technology*

Brussels is getting ready to launch a tax aimed at big tech companies such as *Google*, *Facebook* and *Apple*. The “digital tax” on EU turnover is expected to raise about €5bn.

In the US, pop sensation Rhianna sparked a $1bn sell off in *Snap*, the company that owns the Snapchat app. The singer was the subject of an advert on the platform which asked users if they would "rather slap Rihanna or punch Chris Brown" and she fiercely criticised the company for using Mr Brown’s domestic violence conviction against her as a cheap marketing ploy.

*Engineering*

The hostile takeover battle by *Melrose Industries* for *GKN* is approaching its conclusion, as shareholders will vote on the deal on March 29. Melrose sweetened its offer by £700m, taking its cash-and-shares offer to more than £8bn, but this was rejected by GKN management, which said it “fundamentally undervalued” its business. There were also reports that *Airbus*, the biggest client of GKN’s aerospace business, said it would be “practically impossible” to give new business to the company if it was bought by Melrose.

FTSE 250 listed *Spirax-Sarco *posted better-than-expected full-year revenue and profits, helped by acquisitions and strength in Europe, Middle East and Africa.

*Consumer*

Shares in Anglo-Dutch consumer products giant *Unilever* may no longer be eligible for inclusion in FTSE indexes after its board voted to move its headquarters to Rotterdam. The maker of Dove soap and Lynx deodorant is the third-largest component of the FTSE 100 by market cap and a decision from the index compilers is awaited. The company is cutting costs following a takeover approach by US group *Kraft*. Chief executive Paul Polman, was keen to say the decision had “nothing to do with Brexit” and would not result in the loss of any UK jobs. He also said there would be “no change to tax” paid in the UK.

*Fevertree Drinks*, the maker of upmarket mixers for gin aficionados, posted an excellent set of full-year numbers – but its shares fell. To find out why click here.

Britons flocked to the movies to see films such as Star Wars: The Last Jedi and Dunkirk, boosting revenues at *Cineworld* by almost 12%. The group also expanded last year into the world’s most lucrative cinema market through the purchase of US cinema chain Regal for $3.6bn.

Alongside chairman Tim Martin’s statements supporting Brexit, *JD Wetherspoon* also posted some numbers. In the first half of the year, revenues rose 3.6%, but management said it expected lower like-for-like sales growth and higher costs in the second half.

Shares in gambling group *Sportech* slumped by half after it announced a failure to find a buyer, a profit warning, and a new chief executive in the same day.

*Outsourcing*

Shares in *Kier Group* have been buffeted by trouble at peers such as Carillion and its shares slipped once again following its full-year numbers. There was a sharp rise in net debt from £147m to £239m. This was despite management saying it was it was on track to deliver double-digit profit growth in 2018.

*Property*

Estate agents *Savills* became the latest industry player to warn of a slowdown in the UK property market. “We anticipate a tempering of the strong transaction volumes of recent times in some markets,” chief executive Jeremy Helsby said. The group posted a slightly-better-than-expected 3.5% rise in full-year adjusted profits.

Shares in *Mitie* hit multi-year lows after management revealed costs associated with its turnaround programme will be higher than its previous estimates.

*Supermarkets*

Shares in *Wm Morrison* posted a consensus rating set of full-year numbers and announced a 4p a share special dividend, but its shares fell. Much of the profit uplift was down to lower interest payments as the group reduced its debt.

*Retail*

Trading on the UK high street continues to be tough:

*Toys R Us* will now close or sell all its UK stores in after failing to find a buyer, putting about 3,000 jobs under threat.

Bargain Booze and Wine Rack owner *Conviviality* may need to raise more cash after management revealed it must pay an “unexpected” £30m tax bill by March 29. This prompted its second profit warning in less than a week and the cancellation of its dividend.

*Claire’s Accessories* sought to reassure customers that its UK operations will not be affected by its US counterpart’s bankruptcy filing.

However, there was a small positive glimmer.* French Connection* shares soared after management revealed an unsolicited takeover approach had been made earlier this year. The news came as the group unveiled full-year results, which showed losses narrowed.

*Financials*

Insurer *Prudential *unveiled plans to spin-off its UK and European division from its international businesses as part of a radical break-up of the 170-year-old company.

*CME Group*, the US futures exchange, made a preliminary approach for Michael Spencer's *Nex Group*, a move which some believe will result in a bidding war for the financial technology company.

Operating profits at *Just Group*, a provider of annuities, jumped 35% last year. The results were ahead of analysts’ expectations.

*Nothing on this website should be construed as personal advice based on your circumstances. No news or research item is a personal recommendation to deal.*

  Reported by City A.M. 39 minutes ago.

GERMANTOWN, Md., March 19, 2018 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS), a manufacturer, service provider and developer of advanced cell therapies, today announced that its manufacturing subsidiary, MaSTherCell S.A. (“MaSTherCell”) was appointed by Zelluna Immunotherapy AS (“Zelluna”), a biotechnology company specializing in T-cell receptor (TCR)-based immunotherapies for solid tumors with a high unmet medical need, as its contract development and manufacturing (CDMO) partner for Zelluna’s TCR adoptive cell therapy platform.MaSTherCell will perform process development, optimization and industrialization of the current Zelluna manufacturing process.  The result will be the delivery of a GMP manufacturing platform for Zelluna’s TCR product pipeline.  The manufacturing platform will ensure clinical manufacturing capabilities with increased efficiency and geographical spread.  As a result, Zelluna will have industrialized manufacturing capabilities to support clinical development and commercialization.

Zelluna’s partnership with MaSTherCell at an early developmental phase enables the integration of GMP industrialization concepts into the clinical development of Zelluna TCR therapies, supporting the progress towards clinical trials.  Zelluna expects to commence trials in 2019.

Vered Caplan, Chief Executive Officer of Orgenesis, stated, “I’m proud to build out MaSTherCell’s development activities further with the addition of Zelluna’s platform TCR technology.  Manufacturing and providing process industrialization from the preclinical ground-level offers significant upside potential for us as the TCR products advance into further stages of clinical development, which Zelluna plans to commence in the 2019.  Our world-class facilities are continually being optimized to improve the quality and throughput of CDMO services for Zelluna and all our other customers.”

*About MaSTherCell*
MaSTherCell S.A. is a dynamic and global Contract Development and Manufacturing Organization (CDMO) on a mission to deliver optimized process industrialization capacities to cell therapy organizations, and speed up the arrival of their therapies onto the market.  The company is the subsidiary of Orgenesis Inc. (Nasdaq:ORGS), a cell therapy and regenerative medicine company that is committed to developing a cure for Type 1 diabetes.  The heart of MaSTherCell is a team of highly dedicated experts combining strong experience in cGMP cell therapy manufacturing with a technology-focused approach and a substantial knowledge of the industry.  From technology selection to business modeling, GMP manufacturing, process development, quality management and assay development, MaSTherCell’s teams are fully committed to helping their clients fulfill their objective of providing sustainable and affordable therapies to their patients.  The company operates in a validated and flexible facility located in the strategic center of Europe within the Walloon healthcare cluster, Biowin.  For more information, please visit www.masthercell.com.

*About Zelluna Immunotherapy*
Zelluna Immunotherapy AS specializes in immunotherapies targeting a broad range of solid cancers with a high unmet medical need.  The company is developing a unique portfolio of non-engineered, tumor specific T-cell receptors (TCRs) isolated from long term surviving patients from cancer vaccine trials.  The TCRs combine specificity and affinity to have the potential for a safe and efficient therapy to target a variety of common cancer types.  Zelluna has a long term CRADA with the Department for Cell Therapy at Oslo University Hospital (OUH), providing comprehensive capabilities of TCR development, ranging from lead discovery to clinical translation.  For more information, please visit www.zelluna.com.

*Notice Regarding Forward-Looking Statements*
This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  These forward-looking statements are based upon our current expectations, estimates and projections and reflect our beliefs and assumptions based upon information available to us at the date of this release.  We caution readers that forward-looking statements are predictions based on our current expectations about future events.  These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict.  Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including, our ability to raise additional capital when needed, the sufficiency of working capital, our ability to achieve profitability, the development of our regeneration technology as therapeutic treatment for diabetes which could, if successful, be a cure for Type 1 Diabetes; our technology not functioning as expected; our ability to retain key employees; our ability to satisfy the rigorous regulatory requirements for new procedures; our competitors developing better or cheaper alternatives to our products and the risks and uncertainties discussed under the heading "RISK FACTORS" in Item 1 of our Annual Report on Form 10-K for the fiscal year ended November 30, 2017, and in our other filings with the Securities and Exchange Commission.  We undertake no obligation to revise or update any forward-looking statement for any reason.

*Contacts*
Edison Advisors (investors)
Tirth Patel
646-653-7035
tpatel@edisongroup.com Reported by GlobeNewswire 2 hours ago.

**

· *Citi made a major hire in its European equities team.*
· *20-year-veteran Michela Ferrulli has been hired as the bank's head of equities and sales trading for the Central and Eastern Europe, Middle East, and Asia region.*
· *She previously spent more than six years with Bank of America Merrill Lynch as head of EEMEA equity sales.*

LONDON — American banking giant Citi has made a major hire in its European equities operation.

Twenty-year-veteran Michela Ferrulli has been hired as the bank's head of equities sales and sales trading for the  Central and Eastern Europe, Middle East, and Asia (CEEMEA) region, joining Citi after more than six years with Bank of America Merrill Lynch. At BAML, Ferulli was head of Eastern Europe, Middle East, and Asia (EEMEA) equity sales.

Ferrulli will also act as a managing director at the bank, and will be based in London.

She has previous experience at Citi, having spent 11 years at the firm between 2001 and 2012, working on both the Europe, Middle East, and Asia and Latin America regions.

"We are confident Michela will be a great partner and asset to our business," Mark Robinson, head of cash equities for the EMEA region said in an email to staff. "Her appointment highlights our continued focus on building the momentum of our equities franchise."

Earlier in March, Business Insider reported that Citigroup's stock trading division is undergoing a strategic reorganization, despite solid performance in the space.

Cash equities declined 3% to $9.2 billion across Wall Street last year, but industry sources say Citi's cash equities business, while smaller than competitors at the top of the league tables, actually grew by more than 7% in 2017, BI's Alex Morrell reported.

"Equities has done pretty well this quarter," CFO John Gerspach said at an investor conference a few weeks ago.  "We have a shot at getting to $1 billion of revenues this quarter in Equities."

*SEE ALSO: There’s been a big shakeup at the top of Citigroup’s stock trading business*

Join the conversation about this story »

NOW WATCH: How the super-wealthy hide billions using tax havens and shell companies Reported by Business Insider 1 hour ago.